A Study to Evaluate the Safety and Tolerability of Long-Acting Oral Risperidone (LYN-005) in Participants With Schizophrenia or Schizoaffective Disorder

NCT06878833 · clinicaltrials.gov ↗

PHASE3

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Sponsor stopped operations

Conditions

Schizophrenia
Schizoaffective Disorder

Interventions

DRUG: LYN-005 (risperidone)
DRUG: Placebo for LYN-005
DRUG: IR Risperidone
DRUG: Placebo for IR Risperidone

Sponsor

Lyndra Inc.